Biotech investors, once the envy of Wall Street, have slipped into despondency. After a double-digit decline in 2021, the sector has fallen another twenty percent in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Read more.
Check out last month's top stories. If you like what you see, join our STAT+ community today — and enjoy 25% off your first year. — - ‘Nowhere to hide’: As biotech stocks plummet, an industry is being reshaped by the fallout by Adam Feuerstein, Damian Garde, and Matthew Herper
- With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions by Damian Garde and Adam Feuerstein
- Biotech stocks are a dumpster fire. An analyst explains what’s going on by Adam Feuerstein, Meg Tirrell, and Damian Garde
- ‘We must change’: Health systems invest more aggressively than ever in digital health by Casey Ross
- Once billed as a revolution in medicine, IBM’s Watson Health is sold off in parts by Casey Ross
- The biotech scorecard for the first quarter: 19 stock-moving events to watch by Adam Feuerstein
- In a battle over the future of U.S. health care, a question emerges: Is primary care scalable? by Casey Ross
- Telehealth companies are testing the waters with taking on more risk by Mohana Ravindranath
- Chatbots, surveys, and texts: Telehealth companies cut costs by reimagining the front desk by Mohana Ravindranath
- A preview of the burning biotech and health tech questions at JPM 2022 by STAT Staff
Subscribe now to enjoy 25% off your first year. SUBSCRIBE | 
No comments